Replacement of one ammine in clinically ineffective trans-[PtCl2(NH3)2] (transplatin) by a planar N-heterocycle, thiazole, results in significantly enhanced cytotoxicity. Unlike 'classical' cisplatin {cis-[PtCl2(NH3)2]} or transplatin, modification of DNA by this prototypical cytotoxic transplatinum complex trans-[PtCl2(NH3)(thiazole)] (trans-PtTz) leads to monofunctional and bifunctional intra or interstrand adducts in roughly equal proportions. DNA fragments containing site-specific bifunctional DNA adducts of trans-PtTz were prepared. The structural distortions induced in DNA by these adducts and their consequences for high-mobility group protein recognition, DNA polymerization and nucleotide excision repair were assessed in cell-free media by biochemical methods. Whereas monofunctional adducts of trans-PtTz behave similar to the major intrastrand adduct of cisplatin [J. Kasparkova, O. Novakova, N. Farrell and V. Brabec (2003) Biochemistry, 42, 792-800], bifunctional cross-links behave distinctly differently. The results suggest that the multiple DNA lesions available to trans-planaramine complexes may all contribute substantially to their cytotoxicity so that the overall drug cytotoxicity could be the sum of the contributions of each of these adducts. However, acquisition of drug resistance could be a relatively rare event, since it would have to entail resistance to or tolerance of multiple, structurally dissimilar DNA lesions.

Institute of Biophysics Academy of Sciences of the Czech Republic CZ 61265 Brno Czech Republic

See more in PubMed

Farrell N. Current status of structure–activity relationships of platinum anticancer drugs: activation of the trans geometry. In: Sigel A., Sigel H., editors. Metal Ions in Biological Systems. Vol. 32. New York, Basel, Hong Kong: Marcel Dekker, Inc.; 1996. pp. 603–639. PubMed

Natile G., Coluccia M. In, trans-Platinum compounds in cancer therapy: a largely unexplored strategy for identifying novel antitumor platinum drugs. In: Clarke M.J., Sadler P.J., editors. Metallopharmaceuticals. Vol. 1. Berlin: Springer; 1999. pp. 73–98.

Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog. Nucleic Acid Res. Mol. Biol. 2002;71:1–68. PubMed

Johnson N.P., Butour J.-L., Villani G., Wimmer F.L., Defais M., Pierson V., Brabec V. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 1989;10:1–24.

Zakovska A., Novakova O., Balcarova Z., Bierbach U., Farrell N., Brabec V. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)] Eur. J. Biochem. 1998;254:547–557. PubMed

Bierbach U., Qu Y., Hambley T.W., Peroutka J., Nguyen H.L., Doedee M., Farrel N. Synthesis, structure, biological activity and DNA binding of platinum(II) complexes of the type trans-[PtCl2(NH3)L] (L = planar nitrogen base). Effect of l and cis/trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorg. Chem. 1999;38:3535–3542. PubMed

Brabec V., Neplechova K., Kasparkova J., Farrell N. Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups. J. Biol. Inorg. Chem. 2000;5:364–368. PubMed

Kasparkova J., Novakova O., Farrell N., Brabec V. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Biochemistry. 2003;42:792–800. PubMed

Brabec V., Leng M. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl Acad. Sci. USA. 1993;90:5345–5349. PubMed PMC

Van Beusichem M., Farrell N. Activation of trans geometry in platinum antitumor complexes. Synthesis, characterization and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole, and quinoline. Crystal and molecular structure of trans-dichlorobis (thiazole)platinum(II) Inorg. Chem. 1992;31:634–639.

Brabec V., Reedijk J., Leng M. Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding. Biochemistry. 1992;31:12397–12402. PubMed

Brabec V., Sip M., Leng M. DNA conformational distortion produced by site-specific interstrand cross-link of trans-diamminedichloroplatinum(II) Biochemistry. 1993;32:11676–11681. PubMed

Kasparkova J., Mellish K.J., Qu Y., Brabec V., Farrell N. Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies. Biochemistry. 1996;35:16705–16713. PubMed

Lemaire M.A., Schwartz A., Rahmouni A.R., Leng M. Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl Acad. Sci. USA. 1991;88:1982–1985. PubMed PMC

He Q., Ohndorf U.-A., Lippard S.J. Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA. Biochemistry. 2000;39:14426–14435. PubMed

Matsunaga T., Mu D., Park C.-H., Reardon J.T., Sancar A. Human DNA repair excision nuclease. J. Biol. Chem. 1995;270:20862–20869. PubMed

Novakova O., Kasparkova J., Bursova V., Hofr C., Vojtiskova M., Chen H., Sadler P.J., Brabec V. Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA-binding proteins and repair. Relationship to cytotoxicity. Chem. Biol. 2005;12:121–129. PubMed

Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 1999;59:3968–3971. PubMed

Novakova O., Kasparkova J., Malina J., Natile G., Brabec V. DNA-protein cross-linking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Res. 2003;31:6450–6460. PubMed PMC

Kasparkova J., Novakova O., Marini V., Najajreh Y., Gibson D., Perez J.-M., Brabec V. Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand: Mechanistic studies on antitumor action. J. Biol. Chem. 2003;278:47516–47525. PubMed

Brabec V. Chemistry and structural biology of 1,2-interstrand adducts of cisplatin. In: Kelland L.R., Farrell N.P., editors. Platinum-Based Drugs in Cancer Therapy. Totowa/NJ: Humana Press Inc; 2000. pp. 37–61.

Rice J.A., Crothers D.M., Pinto A.L., Lippard S.J. The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by 40° toward the major groove. Proc. Natl Acad. Sci. USA. 1988;85:4158–4161. PubMed PMC

Bellon S.F., Coleman J.H., Lippard S.J. DNA unwinding produced by site-specific intrastrand cross- links of the antitumor drug cis-diamminedichloroplatinum(II) Biochemistry. 1991;30:8026–8035. PubMed

Koo H.S., Wu H.M., Crothers D.M. DNA bending at adenine.thymine tracts. Nature. 1986;320:501–506. PubMed

Koo H.S., Crothers D.M. Calibration of DNA curvature and a unified description of sequence-directed bending. Proc. Natl Acad. Sci. USA. 1988;85:1763–1767. PubMed PMC

Bellon S.F., Lippard S.J. Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-Pt(NH3)2(N3-cytosine)Cl+ Biophys. Chem. 1990;35:179–188. PubMed

Kostrhunova H., Brabec V. Conformational analysis of site-specific DNA cross-links of cisplatin–distamycin conjugates. Biochemistry. 2000;39:12639–12649. PubMed

Huang H.F., Zhu L.M., Reid B.R., Drobny G.P., Hopkins P.B. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science. 1995;270:1842–1845. PubMed

Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin–DNA adducts. Chem. Rev. 1999;99:2467–2498. PubMed

Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 2001;478:1–21. PubMed

Wei M., Burenkova O., Lippard S.J. Cisplatin sensitivity in Hmgb1−/− and Hmgb1+/+ mouse cells. J. Biol. Chem. 2003;278:1769–1773. PubMed

Ohndorf U.M., Rould M.A., He Q., Pabo C.O., Lippard S.J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature. 1999;399:708–712. PubMed

Kasparkova J., Delalande O., Stros M., Elizondo-Riojas M.A., Vojtiskova M., Kozelka J., Brabec V. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein. Biochemistry. 2003;42:1234–1244. PubMed

Malina J., Kasparkova J., Natile G., Brabec V. Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts. Chem. Biol. 2002;9:629–638. PubMed

Sancar A. DNA excision repair. Annu. Rev. Biochem. 1996;65:43–81. PubMed

Naegeli H. NY: Springer; 1997. Mechanisms of DNA Damage Recognition In Mammalian Cells. PubMed

Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Repair of cisplatin–DNA adducts by the mammalian excision nuclease. Biochemistry. 1996;35:10004–10013. PubMed

Dalbies R., Payet D., Leng M. DNA double helix promotes a linkage isomerization reaction in trans-diamminedichloroplatinum(II)-modified DNA. Proc. Natl Acad. Sci. USA. 1994;91:8147–8151. PubMed PMC

Kasparkova J., Marini V., Najajreh Y., Gibson D., Brabec V. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Biochemistry. 2003;42:6321–6332. PubMed

Suo Z., Lippard S., Johnson K. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry. 1999;38:715–726. PubMed

Johnson K.A. Conformational coupling in DNA-polymerase fidelity. Annu. Rev. Biochem. 1993;62:685–713. PubMed

Hubscher U., Nasheuer H.P., Syvaoja J.E. Eukaryotic DNA polymerases, a growing family. Trends Biochem. Sci. 2000;25:143–147. PubMed

Steitz T.A. DNA polymerases: structural diversity and common mechanisms. J. Biol. Chem. 1999;274:17395–17398. PubMed

Lam W.C., Thompson E.H.Z., Potapova O., Sun X.J.C., Joyce C.M., Millar D.P. 3′-5′ Exonuclease of Klenow fragment: role of amino acid residues within the single-stranded DNA binding region in exonucleolysis and duplex DNA melting. Biochemistry. 2002;41:3943–3951. PubMed

Natile G., Coluccia M. Antitumor active trans-platinum compounds. In: Sigel A., Sigel H., editors. Metal Ions in Biological Systems. Vol. 42. Basel, NY: Marcel Dekker Inc.; 2004. pp. 209–250. PubMed

Perez J.-M., Montero E.I., Quiroga A.G., Fuertes M.A., Alonso C., Navarro-Ranninger C. Cellular uptake, DNA binding and apoptosis induction of cytotoxic trans- [PtCl2(N,N -dimethylamine)(isopropylamine)] in A2780cisR ovarian tumor cells. Metal-Based Drugs. 2001;8:29–37. PubMed PMC

Fojo T., Farrell N., Ortuzar W., Tanimura H., Weinstein J., Myers T.G. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Crit. Rev. Oncol. Hematol. 2005;53:25–34. PubMed

Dalbies R., Boudvillain M., Leng M. Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum(II)-modified single-stranded oligonucleotides. Nucleic Acids Res. 1995;23:949–953. PubMed PMC

Leng M., Schwartz A., Giraud-Panis M.J. Transplatin-modified oligonucleotides as potential antitumor drugs. In: Kelland L.R., Farrell N.P., editors. Platinum-Based Drugs in Cancer Therapy. Totowa/NJ: Humana Press Inc.; 2000. pp. 63–85.

Moggs J.G., Szymkowski D.E., Yamada M., Karran P., Wood R.D. Differential human nucleotide excision repair of paired and mispaired cisplatin–DNA adducts. Nucleic Acids Res. 1997;25:480–491. PubMed PMC

Zamble D.B., Lippard S.J. The response of cellular proteins to cisplatin-damaged DNA. In: Lippert B., editor. Cisplatin. Chemistry and Biochemistry of A Leading Anticancer Drug. Zürich, Weinheim: VHCA, WILEY-VCH; 1999. pp. 73–110.

Fichtinger-Schepman A.M.J., Van der Veer J.L., Den Hartog J.H.J., Lohman P.H.M., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry. 1985;24:707–713. PubMed

Paquet F., Boudvillain M., Lancelot G., Leng M. NMR solution structure of a DNA dodecamer containing a transplatin interstrand GN7-CN3 cross-link. Nucleic Acids Res. 1999;27:4261–4268. PubMed PMC

Malinge J.M., Perez C., Leng M. Base sequence-independent distorsions induced by interstrand cross-links in cis-diaminedichloroplatinum(II)-modified DNA. Nucleic Acids Res. 1994;22:3834–3839. PubMed PMC

Paquet F., Perez C., Leng M., Lancelot G., Malinge J.M. NMR solution structure of a DNA decamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum(II) J. Biomol. Struct. Dyn. 1996;14:67–77. PubMed

Kasparkova J., Brabec V. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. Biochemistry. 1995;34:12379–12387. PubMed

Comparison of the electronic properties, and thermodynamic and kinetic parameters of the aquation of selected platinum(II) derivatives with their anticancer IC50 indexes

Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog

Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin

Pt-bridges in various single-strand and double-helix DNA sequences. DFT and MP2 study of the cisplatin coordination with guanine, adenine, and cytosine